update
NHS rejects suggestion a lack of guidance has slowed biosimilar uptake
The NHS has rejected Napp Pharmaceuticals’ accusation it lacks biosimilar guidance, citing a recently published policy document.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs